CALGARY, Canada I December 4, 2020 I Providence Therapeutics confirmed today that a Clinical Trial Application (CTA) was submitted to Health Canada, December 3, for the mRNA COVID vaccine, PTX-COVID19-B. The company has been keeping Health Canada informed through development of the vaccine candidate.

The Company will not comment further until appropriate discussions have been concluded with Health Canada.

SOURCE: Providence Therapeutics